Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer

Chi Jung Chung, Yu Mei Hsueh, Chyi Huey Bai, Yung Kai Huang, Ya Li Huang, Mo Hsiung Yang, Chien Jen Chen

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Arsenic-metabolism-related genes can regulate the arsenic methylation process and may influence susceptibility to cancer. We evaluated the roles of arsenic metabolism genes on urinary arsenic profiles of repeated measurement with 15-year follow-up (1988-2004) through general linear model (GLM) and assessed the effect of the changed extent of urinary arsenic profiles on cancer risk. Questionnaire information and blood samples and two urines (1988 and 2004) were collected from 208 subjects in an arseniasis hyperendemic area in Taiwan. Profiles for concentrations of urinary arsenic were determined using HPLC-HG-AAS. The relative proportion of each arsenic species was calculated by dividing the concentration of each arsenic species by the total arsenic concentration. Genotyping was done using the 5 nuclease allelic discrimination (Taqman) assay. The incidence of cancer was identified through linking to the National Cancer Registry Systems. The Cox proportional hazards model and survival curves were used in the analyses. After a 15-year follow-up, baseline monomethylarsonic acid percentage (MMA%) and change in MMA% exhibited a significant dose-response relationship with cancer risk. Individuals with a higher baseline MMA% and a lower change in MMA% had the earliest cancer incidence (statistically significant). Through GLM, significant gene effects of arsenic (+3 oxidation state)-methyltransferase (AS3MT) on MMA%, dimethylarsinic acid percentage (DMA%) and DMA/MMA, purine nucleoside phosphorylase (PNP) on DMA% and glutathione S-transferase omega 2 (GSTO2) on inorganic arsenics (InAs%) were found. Our results show that MMA% might be a potential predictor of cancer risk. The change in MMA% was linked to individual cancer susceptibility related to AS3MT rs3740393.

Original languageEnglish
Pages (from-to)1653-1661
Number of pages9
JournalCancer Causes and Control
Volume20
Issue number9
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Arsenic
Methylation
Genes
Neoplasms
Linear Models
Cacodylic Acid
Purine-Nucleoside Phosphorylase
Incidence
Methyltransferases
monomethylarsonic acid
Glutathione Transferase
Taiwan
Proportional Hazards Models
Registries
High Pressure Liquid Chromatography
Urine

Keywords

  • Arsenic metabolism
  • AS3MT
  • Cancer
  • GSTO1
  • GSTO2
  • PNP
  • Polymorphism
  • Repeated measurement
  • Urinary arsenic methylation profile

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. / Chung, Chi Jung; Hsueh, Yu Mei; Bai, Chyi Huey; Huang, Yung Kai; Huang, Ya Li; Yang, Mo Hsiung; Chen, Chien Jen.

In: Cancer Causes and Control, Vol. 20, No. 9, 11.2009, p. 1653-1661.

Research output: Contribution to journalArticle

Chung, Chi Jung ; Hsueh, Yu Mei ; Bai, Chyi Huey ; Huang, Yung Kai ; Huang, Ya Li ; Yang, Mo Hsiung ; Chen, Chien Jen. / Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. In: Cancer Causes and Control. 2009 ; Vol. 20, No. 9. pp. 1653-1661.
@article{f1f1939ed6fd4e709ea07d22cf09441a,
title = "Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer",
abstract = "Arsenic-metabolism-related genes can regulate the arsenic methylation process and may influence susceptibility to cancer. We evaluated the roles of arsenic metabolism genes on urinary arsenic profiles of repeated measurement with 15-year follow-up (1988-2004) through general linear model (GLM) and assessed the effect of the changed extent of urinary arsenic profiles on cancer risk. Questionnaire information and blood samples and two urines (1988 and 2004) were collected from 208 subjects in an arseniasis hyperendemic area in Taiwan. Profiles for concentrations of urinary arsenic were determined using HPLC-HG-AAS. The relative proportion of each arsenic species was calculated by dividing the concentration of each arsenic species by the total arsenic concentration. Genotyping was done using the 5 nuclease allelic discrimination (Taqman) assay. The incidence of cancer was identified through linking to the National Cancer Registry Systems. The Cox proportional hazards model and survival curves were used in the analyses. After a 15-year follow-up, baseline monomethylarsonic acid percentage (MMA{\%}) and change in MMA{\%} exhibited a significant dose-response relationship with cancer risk. Individuals with a higher baseline MMA{\%} and a lower change in MMA{\%} had the earliest cancer incidence (statistically significant). Through GLM, significant gene effects of arsenic (+3 oxidation state)-methyltransferase (AS3MT) on MMA{\%}, dimethylarsinic acid percentage (DMA{\%}) and DMA/MMA, purine nucleoside phosphorylase (PNP) on DMA{\%} and glutathione S-transferase omega 2 (GSTO2) on inorganic arsenics (InAs{\%}) were found. Our results show that MMA{\%} might be a potential predictor of cancer risk. The change in MMA{\%} was linked to individual cancer susceptibility related to AS3MT rs3740393.",
keywords = "Arsenic metabolism, AS3MT, Cancer, GSTO1, GSTO2, PNP, Polymorphism, Repeated measurement, Urinary arsenic methylation profile",
author = "Chung, {Chi Jung} and Hsueh, {Yu Mei} and Bai, {Chyi Huey} and Huang, {Yung Kai} and Huang, {Ya Li} and Yang, {Mo Hsiung} and Chen, {Chien Jen}",
year = "2009",
month = "11",
doi = "10.1007/s10552-009-9413-0",
language = "English",
volume = "20",
pages = "1653--1661",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "9",

}

TY - JOUR

T1 - Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer

AU - Chung, Chi Jung

AU - Hsueh, Yu Mei

AU - Bai, Chyi Huey

AU - Huang, Yung Kai

AU - Huang, Ya Li

AU - Yang, Mo Hsiung

AU - Chen, Chien Jen

PY - 2009/11

Y1 - 2009/11

N2 - Arsenic-metabolism-related genes can regulate the arsenic methylation process and may influence susceptibility to cancer. We evaluated the roles of arsenic metabolism genes on urinary arsenic profiles of repeated measurement with 15-year follow-up (1988-2004) through general linear model (GLM) and assessed the effect of the changed extent of urinary arsenic profiles on cancer risk. Questionnaire information and blood samples and two urines (1988 and 2004) were collected from 208 subjects in an arseniasis hyperendemic area in Taiwan. Profiles for concentrations of urinary arsenic were determined using HPLC-HG-AAS. The relative proportion of each arsenic species was calculated by dividing the concentration of each arsenic species by the total arsenic concentration. Genotyping was done using the 5 nuclease allelic discrimination (Taqman) assay. The incidence of cancer was identified through linking to the National Cancer Registry Systems. The Cox proportional hazards model and survival curves were used in the analyses. After a 15-year follow-up, baseline monomethylarsonic acid percentage (MMA%) and change in MMA% exhibited a significant dose-response relationship with cancer risk. Individuals with a higher baseline MMA% and a lower change in MMA% had the earliest cancer incidence (statistically significant). Through GLM, significant gene effects of arsenic (+3 oxidation state)-methyltransferase (AS3MT) on MMA%, dimethylarsinic acid percentage (DMA%) and DMA/MMA, purine nucleoside phosphorylase (PNP) on DMA% and glutathione S-transferase omega 2 (GSTO2) on inorganic arsenics (InAs%) were found. Our results show that MMA% might be a potential predictor of cancer risk. The change in MMA% was linked to individual cancer susceptibility related to AS3MT rs3740393.

AB - Arsenic-metabolism-related genes can regulate the arsenic methylation process and may influence susceptibility to cancer. We evaluated the roles of arsenic metabolism genes on urinary arsenic profiles of repeated measurement with 15-year follow-up (1988-2004) through general linear model (GLM) and assessed the effect of the changed extent of urinary arsenic profiles on cancer risk. Questionnaire information and blood samples and two urines (1988 and 2004) were collected from 208 subjects in an arseniasis hyperendemic area in Taiwan. Profiles for concentrations of urinary arsenic were determined using HPLC-HG-AAS. The relative proportion of each arsenic species was calculated by dividing the concentration of each arsenic species by the total arsenic concentration. Genotyping was done using the 5 nuclease allelic discrimination (Taqman) assay. The incidence of cancer was identified through linking to the National Cancer Registry Systems. The Cox proportional hazards model and survival curves were used in the analyses. After a 15-year follow-up, baseline monomethylarsonic acid percentage (MMA%) and change in MMA% exhibited a significant dose-response relationship with cancer risk. Individuals with a higher baseline MMA% and a lower change in MMA% had the earliest cancer incidence (statistically significant). Through GLM, significant gene effects of arsenic (+3 oxidation state)-methyltransferase (AS3MT) on MMA%, dimethylarsinic acid percentage (DMA%) and DMA/MMA, purine nucleoside phosphorylase (PNP) on DMA% and glutathione S-transferase omega 2 (GSTO2) on inorganic arsenics (InAs%) were found. Our results show that MMA% might be a potential predictor of cancer risk. The change in MMA% was linked to individual cancer susceptibility related to AS3MT rs3740393.

KW - Arsenic metabolism

KW - AS3MT

KW - Cancer

KW - GSTO1

KW - GSTO2

KW - PNP

KW - Polymorphism

KW - Repeated measurement

KW - Urinary arsenic methylation profile

UR - http://www.scopus.com/inward/record.url?scp=70350614432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350614432&partnerID=8YFLogxK

U2 - 10.1007/s10552-009-9413-0

DO - 10.1007/s10552-009-9413-0

M3 - Article

C2 - 19680750

AN - SCOPUS:70350614432

VL - 20

SP - 1653

EP - 1661

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 9

ER -